Abivax Aligns with FDA on Obefazimod NDA Submission
PARIS, France, July 30, 2026 Abivax SA announced the successful completion of a positive pre-New Drug Application (pre-NDA) interaction...
Abivax
Advertisement
Abivax Reports Positive Phase 3 Obefazimod Maintenance Data
PARIS, France, June 29, 2026 Abivax SA announced positive topline results from ABTECT Maintenance Part 2, the supplemental portion...
Abivax’s Obefazimod Delivers Landmark Phase 3 Success in Ulcerative Colitis
PARIS, France, June 1, 2026 Abivax announced positive topline results from its pivotal Phase 3 ABTECT maintenance trial evaluating...
Abivax Reports Strong Three-Year Remission Results for Obefazimod in Ulcerative Colitis
PARIS, France, May 22, 2026 Abivax announced new three-year interim data from Study 108 showing that obefazimod maintained durable...
Advertisement
